EVPL抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P06439(EVPL Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

EVPL antibody targets the Epidermal Variegated Palmidactylia-Like (EVPL) protein, a component of desmosomal junctions critical for maintaining epithelial integrity. EVPL, also known as plakophilin-4. belongs to the armadillo protein family and plays a role in cell-cell adhesion, tissue stability, and signal transduction. It is expressed in stratified epithelia and hair follicles, where its dysfunction has been linked to skin disorders like erythrokeratodermia and hypotrichosis. Research highlights its involvement in pathological conditions, including cancers, where altered desmosomal protein expression correlates with tumor progression and metastasis.

EVPL antibodies are primarily monoclonal or polyclonal tools developed using recombinant protein fragments or peptide immunogens. They enable detection of EVPL in techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding studies on epithelial morphogenesis, disease mechanisms, and therapeutic targets. Recent advancements in antibody engineering have improved specificity, reducing cross-reactivity with related plakophilins.

Current research focuses on leveraging EVPL antibodies for diagnostic applications, such as assessing desmosomal disruption in skin biopsies, and exploring therapeutic potential in modulating cell adhesion in cancers. Challenges remain in understanding EVPL's isoform-specific roles and optimizing antibodies for clinical use. Continued studies may unlock novel insights into epithelial biology and targeted treatments. (Word count: 246)